MBX Biosciences Announces The Appointment Of Dr. Andreas Moraitis As Senior Vice President Of Clinical Development To Lead Clinical Strategy

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, has announced the appointment of Dr. Andreas Moraitis as Senior Vice President of Clinical Development. Dr. Moraitis is a board-certified endocrinologist with deep expertise in leading clinical programs targeting endocrine and metabolic conditions. He brings over ten years of industry experience, most recently serving at Corcept Therapeutics, where he directed the clinical development of therapies for rare endocrine diseases. 

At Corcept, he played a key role in designing and executing multiple clinical trials, supported the New Drug Application (NDA) submission for relacorilant in hypercortisolism, and worked closely with regulatory agencies throughout various stages of drug development. Before transitioning into industry, Dr. Moraitis held academic positions, including Clinical Assistant Professor in the Endocrine Oncology Program at the University of Michigan and volunteer clinical faculty at the VA Medical Center in Orlando. He completed his clinical fellowship in Adult and Reproductive Endocrinology at the National Institutes of Health (NIH).

Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences, said in a statement, “Canvuparatide has the potential to provide a meaningful new option for people living with hypoparathyroidism, an area where patients continue to face significant unmet needs. Andreas’ deep expertise in endocrinology and proven track record of leading clinical development programs, from Investigational New Drug (IND) application to New Drug Application (NDA), make him an exceptional addition to our leadership team as we advance canvuparatide and our growing pipeline of obesity and rare disease product candidates.”

Dr. Moraitis mentioned, “I have dedicated my career to developing new approaches for people living with complex endocrine conditions. I am delighted to join MBX and look forward to working with this talented and experienced team to advance canvuparatide and help bring new potential treatments to patients whose needs are not adequately managed by existing treatments.”

Dr. Moraitis earned his medical degree from the National and Kapodistrian University of Athens and is board-certified by the American Board of Internal Medicine in internal medicine as well as endocrinology, metabolism, and diabetes. Earlier in his career, he also served in the Greek Military Air Force. With his combination of clinical, academic, and regulatory experience, Dr. Moraitis is expected to play a vital role in advancing MBX Biosciences’ pipeline of novel therapies aimed at addressing unmet needs in endocrine and metabolic health.